JPMorgan analyst Brian Cheng downgraded Allogene Therapeutics (ALLO) to Neutral from Overweight with no price target after the company reported a fatal event in cemacabtagene ansegedleucel, or cema-cel’s, pivotal front-line consolidation large B-cell lymphoma ALPHA 3 study. The announcement “came as a surprise,” says the analyst, who finds it “difficult to remain confident in cema-cel” following a recent series of setbacks. After updating the firm’s model to reflect today’s announcement, the firm is lowering penetration assumptions and probability of success for cema-cel in first-line consolidation LBCL, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $7 from $9 at Oppenheimer
- Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
- Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
- Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment
- Allogene Therapeutics management to meet with Piper Sandler